Publications by authors named "Martin Zimen"
Article Synopsis
- The study evaluated what factors affect how long biologic drugs work for children with Crohn's disease, using data from the Czech National Registry.
- Findings showed that infliximab had a higher discontinuation risk compared to adalimumab, and that starting treatment sooner after diagnosis improved sustainability.
- The study concluded that the effectiveness of these treatments isn't equal, as infliximab requires more frequent adjustments and immunosuppression than adalimumab.
